Loxo Oncology, Inc.
CIK 0001581720
Revenue (TTM)
—
Q3 Oct 2018
Net Income (TTM)
−$115.67M
+71.9% YoY
Q3 Oct 2018
EPS Diluted (TTM)
—
Q3 Oct 2018
Gross Margin
—
Q3 Oct 2018
Operating Margin
—
Q3 Oct 2018
Net Margin
—
Q3 Oct 2018
Free Cash Flow (TTM)
$106.67M
Q3 Oct 2018
Cash
$136.11M
Q3 Oct 2018
Total Debt
—
Q3 Oct 2018
Shares Outstanding
30.61M sh
Q3 Oct 2018
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.